Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SuperGen acquires equity interest in AVI BioPharma and negotiating rights to Avicine

Dec. 28, 1999

BLA filing for Campath announced

Dec. 27, 1999

AVI BioPharma's cancer vaccine enters phase III development

Dec. 27, 1999

DSMB recommends continuation of Allovectin-7 trials

Dec. 23, 1999

CeaVac trial reaches accrual goal; phase II trial will be expanded to phase III

Dec. 23, 1999

Transgene presents phase II data for cancer vaccine

Dec. 23, 1999

StressGen's new treatment for cervical dysplasia successfully completes phase I study

Dec. 14, 1999

Cell Genesys receives payment from Japan Tobacco for cancer vaccine milestone

Dec. 14, 1999

KRN-7000-stimulated human cells effective in vitro against melanoma cell lines

Dec. 13, 1999

ImmunoGen's lead tumor-activated prodrug enters the clinic

Dec. 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...